Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) SVP Thomas Richard Kassberg unloaded 20,000 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $53.91, for a total transaction of $1,078,200.00. Following the transaction, the senior vice president now directly owns 105,804 shares in the company, valued at approximately $5,703,894. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Separately, analysts at Robert W. Baird initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 15th. They set an “outperform” rating and a $64.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $74.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 0.65% during mid-day trading on Thursday, hitting $56.06. The stock had a trading volume of 921,294 shares. Ultragenyx Pharmaceutical has a 1-year low of $32.02 and a 1-year high of $69.774. The stock has a 50-day moving average of $49.12 and a 200-day moving average of $46.56. The company’s market cap is $1.777 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.42) by $0.03. On average, analysts predict that Ultragenyx Pharmaceutical will post $-2.08 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.